Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Statistics in Medicine
|
June 24, 2003
Joint models for efficient estimation in proportional hazards regression models
Peter Slasor, Nan Laird
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
June 5, 2003
Does the sedative agent facilitate emergency rapid sequence intubation?
Marco L A Sivilotti, Michael R Filbin, Heather E Murray, et al.
Clinical Therapeutics
|
December 14, 2016
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study
Brian Long, Troy Tompkins, Celeste Decker, et al.
Frontiers in Neurology
|
March 31, 2025
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa
Angela Schulz, Christoph Schwering, Eva Wibbeler, et al.
Clinical Immunology (Orlando, Fla.)
|
September 12, 2018
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
Anu Cherukuri, Heather Cahan, Greg de Hart, et al.
The New England Journal of Medicine
|
April 25, 2018
Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Angela Schulz, Temitayo Ajayi, Nicola Specchio, et al.
Plos One
|
May 22, 2024
Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
Nicola Specchio, Paul Gissen, Emily de Los Reyes, et al.
Clinical and Translational Science
|
November 17, 2020
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
Aryun Kim, Anita Grover, Kevin Hammon, et al.
Journal of Inherited Metabolic Disease
|
May 10, 2014
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
Christian J Hendriksz, Barbara Burton, Thomas R Fleming, et al.
The Lancet. Child & Adolescent Health
|
August 19, 2018
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study
Miriam Nickel, Alessandro Simonati, David Jacoby, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Statistics in Medicine
|
June 24, 2003
Joint models for efficient estimation in proportional hazards regression models
Peter Slasor, Nan Laird
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
June 5, 2003
Does the sedative agent facilitate emergency rapid sequence intubation?
Marco L A Sivilotti, Michael R Filbin, Heather E Murray, et al.
Clinical Therapeutics
|
December 14, 2016
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study
Brian Long, Troy Tompkins, Celeste Decker, et al.
Frontiers in Neurology
|
March 31, 2025
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa
Angela Schulz, Christoph Schwering, Eva Wibbeler, et al.
Clinical Immunology (Orlando, Fla.)
|
September 12, 2018
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
Anu Cherukuri, Heather Cahan, Greg de Hart, et al.
The New England Journal of Medicine
|
April 25, 2018
Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Angela Schulz, Temitayo Ajayi, Nicola Specchio, et al.
Plos One
|
May 22, 2024
Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
Nicola Specchio, Paul Gissen, Emily de Los Reyes, et al.
Clinical and Translational Science
|
November 17, 2020
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
Aryun Kim, Anita Grover, Kevin Hammon, et al.
Journal of Inherited Metabolic Disease
|
May 10, 2014
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
Christian J Hendriksz, Barbara Burton, Thomas R Fleming, et al.
The Lancet. Child & Adolescent Health
|
August 19, 2018
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study
Miriam Nickel, Alessandro Simonati, David Jacoby, et al.
Page
of 2